Abstract:Objective — to evaluate the effectiveness and safety of the use of original schemes of complex treatment of patients with non‐alcoholic fatty liver disease (NAFLD) and renal parenchymal arterial hypertension (RPAH). Materials and methods. Investigation involved 45 patients with NAFLD and RPAH grade 2. The state of the liver was assessed with ultrasound examination. Liver steatosis, inflammation and fibrosis were evaluated with the use of FibroMax test (France). Blood biochemistry was analyzed with the standard generally accepted methods: lipids, aminotransferases, gamma‐glutamyl transpeptidase (GGTP), glucose, glycosylated hemoglobin, insulin, HOMA index, glomerular filtration rate (GFR) were determined according to the CKD‐EPI formula. Blood Levels of cytokeratin‐18, adiponectin, fetuin A, tumor necrosis factor‐α, and interleukin‐6 were determined by ELISA. The indicators of malondialdehyde and diene conjugates and superoxide dismutase were determined by spectrophotometry. Patients were divided into two groups. Group A patients (n=23) received losartan 25—50 mg/day in combination with indapamide 1.5—2.5 mg and atorvastatin 10—20 mg/day for 12 months. Group B patients (n=22) received extended complex treatment (ECT) losartan 25—50 mg/day in combination with indapamide 1.5—2.5 mg and atorvastatin 10—20 mg/day in combination with complex ω‐3 polyunsaturated fatty acids in a dose of 2 g/day and ursodeoxycholic acid (UDCA) in a dose of 10 mg/kg/day for 12 months. Results. Both regimens of 12‐month complex treatment of patients with NAFLD and RPAH effectively improved parameters of blood pressure, carbohydrate, lipid metabolism, renal function, inflammation and oxidative stress indicators. There was no significant difference in the effects on anthropometric indicators and systolic BP (p>0.05). Meanwhile, there was a significant difference in favor of ECT according to the diastolic BP — the difference in the shift of the indicator was 2.213 mm Hg (p<0.01). Almost all laboratory «liver» indicators, except for ALT, decreased to a greater extent in patients receiving the ECT regimen. Thus, according to the GGTP the shift difference was 13.970 U/L (p<0.001), and according to the cytokeratin‐18 the shift difference was 58.126 U/L (p<0.001). There was also a significantly greater effect of ECT on fibrosis, steatosis and inflammation of the liver according to FibroMax data. Thus, the difference between shifts was 0.08 (p<0.01), 0.12 (p<0.001) and 0.10 (p<0.01), respectively. The results of the comparative assessment of lipid and carbohydrate metabolism indicators were heterogeneous. Thus, the shift in total cholesterol was significantly greater in the ECT group and was 0.621 mmol/L (p 0.05). There was also a significant difference between shifts in glycosylated hemoglobin in favor of the ECT scheme, the difference was 0.197% (p 0.05). The difference in blood creatinine and GFR shifts was significant and was 6.806 mol/L and 6.156 ml/min/1.73 m2, respectively (p 0.05). Conclusions. The treatment scheme of a 12‐month complex treatment with the addition of ω‐3 polyunsaturated fatty acids 2 g/day and UDCA 10 mg/kg/day is more effective in terms of impact on clinical and laboratory indicators.

Real-world evidence for beneficial effects of essential phospholipids in patients with non-alcoholic fatty liver disease

Meta-analysis and narrative review confirm the benefit of essential phospholipids in non-alcoholic fatty liver disease

Real-world data support the use of essential phospholipids in non-alcoholic fatty liver disease

Essential phospholipids impact cytokine secretion and alter lipid-metabolizing enzymes in human hepatocyte cell lines

Elevated Serum Phosphatidylcholine (16:1/22:6) Levels Promoted by Fish Oil and Vitamin D3 Are Highly Correlated with Biomarkers of Non-Alcoholic Fatty Liver Disease in Chinese Subjects.

Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic comorbidities: real-life observational study from Russia

Effect of essential phospholipids on hepatic steatosis in metabolic dysfunction-associated steatotic liver disease associated with type 2 diabetes mellitus and/or hyperlipidemia and/or obesity: study protocol of a randomized, double-blind, phase IV clinical trial

Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)

Efficacy and Safety of a Fixed Combination of Glycyrrhizic Acid and Essential Phospholipids in Non-Alcoholic Fatty and Alcoholic Liver Disease: Results from Randomized Placebo-Controlled Trials

Efficacy of Orlistat in Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.

Study on the Relationship between Phospholipids and Nonalcoholic Fatty Liver Disease

Efficacy and Safety of Omega-3 Fatty Acids on Liver-Related Outcomes in Patients with Nonalcoholic Fatty Liver Disease A Protocol for a Systematic Review and Meta-Analysis

The efficacy of novel metabolic targeted agents and natural plant drugs for nonalcoholic fatty liver disease treatment: A PRISMA-compliant network meta-analysis of randomized controlled trials

Comparison of Egg Yolk and Soybean Phospholipids on Hepatic Fatty Acid Profile and Liver Protection in Rats Fed a High-Fructose Diet

Changes in the serum metabolomic profiles of subjects with NAFLD in response to n-3 PUFAs and phytosterol ester: a double-blind randomized controlled trial

Safety and efficacy of dyslipidemia treatment in NAFLD patients: a meta-analysis of randomized controlled trials

Evaluation of the effectiveness of long-term complex treatment schemes for patients with non-alcoholic fatty liver disease in combination with renal parenchymal arterial hypertension

Effects of Hepatoprotectants in the Treatment of Nonalcoholic Fatty Liver Disease

Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence

Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis

Research progress, challenges and perspectives of phospholipids metabolism in the LXR‐LPCAT3 signaling pathway and its relation to NAFLD (Review)